Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Introduction: Physicians are life-long learners and life-long educators. Through their entire careers, they educate patients, residents, medical students, and other health care professionals. There is currently no requirement for medical schools in the United States to provide courses in teaching or communication.
View Article and Find Full Text PDFClinical trials for implantable neural prostheses: understanding the ethical and technical requirements.
Lancet Digit Health
January 2025
Laboratory for Neuroengineering, Department of Health Science and Technology, Institute for Robotics and Intelligent Systems, ETH Zürich, Zürich, Switzerland; NeuroEngineering Laboratory, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria. Electronic address:
Neuroprosthetics research has entered a stage in which animal models and proof-of-concept studies are translated into clinical applications, often combining implants with artificial intelligence techniques. This new phase raises the question of how clinical trials should be designed to scientifically and ethically address the unique features of neural prostheses. Neural prostheses are complex cyberbiological devices able to acquire and process data; hence, their assessment is not reducible to only third-party safety and efficacy evaluations as in pharmacological research.
View Article and Find Full Text PDFMaintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome. The ELECTRA-SIRIO 2 investigators' viewpoint.
Cardiol J
January 2025
Department of Clinical and Interventional Cardiology, Sassari University Hospital, Sassari, Italy.
According to the ESC guidelines, cangrelor may be considered in P2Y12-inhibitor-naïve acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). The aim of this review is to summarize available evidence on the optimal maintenance therapy with P2Y12 receptor inhibitor after cangrelor. Transitioning from cangrelor to a thienopyridine, but not ticagrelor, can be associated with a drug-drug interaction (DDI); therefore, a ticagrelor loading dose (LD) can be given any time before, during, or at the end of a cangrelor infusion, while a LD of clopidogrel or prasugrel should be administered at the time the infusion of cangrelor ends or within 30 minutes before the end of infusion in the case of a LD of prasugrel.
View Article and Find Full Text PDFA Systematic Blueprint to Ligand the Proteome.
J Med Chem
January 2025
Discovery Sciences, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States.
The Target 2035 initiative is an ambitious proposal to discover pharmacological tools across the human proteome. This Viewpoint summarizes an approach inspired by that goal leveraging DNA-encoded library coupled with machine learning approaches to assess the ligandability of the WD40 repeat target class of proteins.
View Article and Find Full Text PDFModern-Day Management of the Dysglycemic Continuum: An Expert Viewpoint from the Arabian Gulf.
Diabetes Metab Syndr Obes
December 2024
Global Research & Development Medical - MU CM&E, Merck Healthcare KGaA, Darmstadt, Germany.
Prediabetes is the first stage of a continuum that extends through the diagnosis of clinical type 2 diabetes towards long-standing diabetes with multiple comorbidities. The diagnosis of prediabetes provides an opportunity to interrupt the diabetes continuum at an early stage to ensure long-term optimization of clinical outcomes. All people with prediabetes should receive intervention to improve their lifestyles (quality of diet and level of physical activity), as this has been proven beyond doubt to reduce substantially the risk of conversion to diabetes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!